Welcome to our dedicated page for Lantheus Holding news (Ticker: LNTH), a resource for investors and traders seeking the latest updates and insights on Lantheus Holding stock.
Lantheus Holdings, Inc. reports news on its radiopharmaceutical business, including diagnostic imaging agents, radiotherapeutic assets, regulatory decisions and financial results. The company organizes revenue around Radiopharmaceutical Oncology, Precision Diagnostics and Strategic Partnerships and Other Revenue, with products used by hospitals, independent imaging centers, government facilities and distribution partners in the United States and abroad.
Recurring updates include quarterly earnings, business guidance, FDA activity for products such as PYLARIFY TruVu, PYLARIFY, Lutetium Lu 177 Dotatate (PNT2003) and LNTH-2501, share repurchases, investor presentations and strategic updates involving radiodiagnostics and radiotherapeutic programs.
Lantheus (NASDAQ: LNTH) reported second quarter 2026 worldwide revenue of $388.2 million, up 2.7% year over year. GAAP net income was $75.0 million, with GAAP diluted EPS of $1.11 versus $1.12 a year ago; adjusted diluted EPS was $1.55 versus $1.57.
PYLARIFY sales were $240.4 million (down 4.1%), DEFINITY sales were $88.3 million (up 5.2%), and Neuraceq contributed $39.6 million. Operating income increased 13.9% to $100.2 million. Cash and equivalents rose to $593.3 million, and the company has access to a $750 million revolver. On August 3, 2026, Lantheus entered a definitive agreement for Curium US Holdings to acquire all shares for $102.50 per share in cash plus non-transferable CVRs of up to $12.00 per share, implying total potential consideration of up to $114.50 per share and transaction value of up to $8.0 billion. Lantheus suspended its full-year 2026 guidance and will not host a Q2 earnings call.
Curium and Lantheus (NASDAQ: LNTH) signed a definitive agreement for Curium US to acquire all Lantheus shares for $102.50 per share in cash at closing, plus non-transferable Contingent Value Rights (CVRs) of up to $12.00 per share tied to commercial milestones, for total potential consideration of $114.50 per share and an aggregate transaction value of up to $8.0 billion.
According to Lantheus, the cash offer implies premiums of 38% to its unaffected 60-day VWAP, 29% to its 30-day VWAP, and 21% to its unaffected closing price as of May 21, 2026. CVR milestones include sales thresholds for global prostate cancer diagnostics, neurology diagnostics, and the DEFINITY business through 2030, with no assurance of payout. The deal, unanimously approved by Lantheus’ board and expected to be financed with debt and equity, is targeted to close in the first half of 2027, subject to shareholder and regulatory approvals. Lantheus will remain public until closing, after which it will become privately held, and has suspended its FY 2026 guidance and earnings call due to the pending transaction.
Lantheus (NASDAQ: LNTH) will host a second quarter 2026 earnings conference call and webcast at 8:00 a.m. Eastern Time on Thursday, August 6, 2026. The event will cover financial results and a business update for the quarter. Participants must register online via the company’s investor relations events calendar. Lantheus encourages registration 15 minutes before the start time. A replay of the webcast will be available about two hours after the event and will remain archived on the same webpage for at least 30 days.
Lantheus (NASDAQ: LNTH) received a Complete Response Letter (CRL) from the FDA for its LNTH-2501 (Ga 68 edotreotide) NDA, a PET imaging kit for SSTR+ neuroendocrine tumors. The FDA cannot approve by the June 29, 2026 PDUFA date due to unresolved third-party manufacturing facility inspection-related conditions, with no safety, efficacy, or data concerns cited.
Lantheus (NASDAQ: LNTH) announced that Vice President of External Manufacturing John Wiggins will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference at 8:40 a.m. ET on Tuesday, June 9. A live webcast and 30-day replay will be available on the company’s investor website.
Lantheus (NASDAQ: LNTH) reported that an image from its investigational thrombus-imaging agent LNTH-2513 (18F-GP1) PET/CT received SNMMI’s 2026 Image of the Year. In a 46-patient study for suspected lower-extremity DVT, LNTH-2513 showed high diagnostic accuracy versus venous ultrasonography and was well tolerated.
Lantheus (NASDAQ: LNTH) announced that John Wiggins, Vice President, External Manufacturing, will join a fireside chat at the William Blair 46th Annual Growth Stock Conference at 12:10 p.m. ET on Wednesday, June 3. A live webcast and 30-day replay will be available via the company’s investor website.
Lantheus (NASDAQ: LNTH) will present new radiodiagnostic data at the 2026 SNMMI Annual Meeting in Los Angeles from May 30 – June 2, 2026.
Presentations cover PSMA-PET with Piflufolastat F18 in prostate cancer management and 18F-GP1 PET/CT for diagnosing acute deep vein thrombosis.
Lantheus (NASDAQ:LNTH) will present new radiopharmaceutical data at the 2026 ASCO Annual Meeting, held May 29–June 2, 2026 in Chicago.
Presentations include a Phase 1/2 study of LNTH-2403 in relapsed/refractory osteosarcoma and a publication-only abstract on real-world use of piflufolastat F 18 in early-stage prostate cancer.
Lantheus (NASDAQ: LNTH) reported Q1 2026 revenue of $377.3M and GAAP net income of $118.4M. GAAP fully diluted EPS was $1.80 versus $1.02 a year earlier; adjusted EPS was $1.46. The company received FDA approval for PYLARIFY TruVu with a phased launch planned in Q4 2026 and achieved tentative approval for PNT2003. Cash and equivalents totaled $498.6M, including $31.4M from the SPECT divestiture. Full-year 2026 guidance was reaffirmed at $1.4B–$1.45B revenue and adjusted EPS $5.00–$5.25.